May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Intravitreal Bevacizumab in Neovascular Age-Related Macular Degeneration: One Year Results
Author Affiliations & Notes
  • J. Kuntz
    Oftalmologia, Pontificia Univ Catolica do Parana, Curitiba, Brazil
  • M. J. Nóbrega
    Hospital de Olhos Sadalla Amin Ghanem, Joinville, Brazil
    University of Joinville, Joinville, Brazil
  • F. J. Novelli
    Hospital de Olhos Sadalla Amin Ghanem, Joinville, Brazil
  • J. G. O. Moraes
    Oftalmologia, Pontificia Univ Catolica do Parana, Curitiba, Brazil
    Oftalmoclínica, Curitiba, Brazil
  • E. L. Rosa
    Hospital de Olhos Sadalla Amin Ghanem, Joinville, Brazil
  • T. B. Berti
    Hospital de Olhos Sadalla Amin Ghanem, Joinville, Brazil
  • S. A. Coral
    Hospital de Olhos Sadalla Amin Ghanem, Joinville, Brazil
  • Footnotes
    Commercial Relationships  J. Kuntz, None; M.J. Nóbrega, None; F.J. Novelli, None; J.G.O. Moraes, None; E.L. Rosa, None; T.B. Berti, None; S.A. Coral, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 327. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Kuntz, M. J. Nóbrega, F. J. Novelli, J. G. O. Moraes, E. L. Rosa, T. B. Berti, S. A. Coral; Intravitreal Bevacizumab in Neovascular Age-Related Macular Degeneration: One Year Results. Invest. Ophthalmol. Vis. Sci. 2008;49(13):327.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the long term efficacy and safety of intravitreal bevacizumab (Avastin, Genentech) for the treatment of neovascular age-related macular degeneration (AMD) in two eye clinics in southern Brazil, Sadalla Amin Ghanem (Joinville/SC) and Oftalmoclínica (Curitiba/PR).

Methods: : Retrospective chart review of 31 consecutive patients with neovascular AMD who received one or more intravitreal injections of bevacizumab and completed at least one year of follow-up. Patients underwent visual acuity (VA) testing and ophthalmoscopic evaluation at baseline and follow-up examinations; optical coherence tomography and fluorescein angiography were usually performed at first visit and then as needed basis. Cases with prior verteporfirin photodynamic therapy, photocoagulation and intravitreal or periocular injections of triamcinolone or other anti-angiogenic drugs were excluded. After written informed consent was obtained, patients were treated with an intravitreal bevacizumab dose of 0.05ml (1.25mg) to 0.1ml (2.50mg). Reinjections were performed if worsening was observed after an initial favorable functional response.

Results: : Thirty-two eyes of 31 patients were included in this study (41.9% male, 58.1% female) with a mean age of 75.3 years-old (59-92 years); they received an average of 2.8 injections (range 1-6). Twenty-two eyes (68.8%) had improved or stable VA with a mean variation from 0.76 logMAR before treatment to 0.74 logMAR at last follow-up visit. No significant ocular or systemic side effects were noted.

Conclusions: : This study suggests that bevacizumab appears to be a safe and effective treatment for neovascular AMD after one year of initial therapy. Further studies are necessary to validate these preliminary findings.

Keywords: age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×